This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join us on 24 September 2024 to hear from Dr Eleni Tholouli, Consultant Haematologist & the Director of the Adult Stem Cell Transplant Unit discussing 'Fit for Intensive Treatment - How do we Decide?' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
Prescribing information can be found at the bottom of the page.
Join us on 24 September 2024 to hear from Dr Eleni Tholouli, Consultant Haematologist & the Director of the Adult Stem Cell Transplant Unit discussing 'Fit for Intensive Treatment - How do we Decide?' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
Dr Eleni Tholouli graduated in Germany and completed her haematology specialist training in Manchester where she also undertook a PhD at Manchester University investigating prognostic molecular markers in acute myeloid leukaemia. She consolidated her transplant experience as a Transplant Fellow at the Fred Hutchinson Research Cancer Centre, Seattle, USA, one of the world’s largest transplant centres. Her expertise covers a wide range of haemato-oncological malignancies (leukaemia, myeloma, lymphoma) and non-malignant disorders (bone marrow failures, aplasia). She is the Director of the Adult Stem Cell and Immunotherapy Unit and Haemato-Oncology Pathway Board at Manchester Cancer.
Mylotarg®▼(gemtuzumab ozogamicin)
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024